MSK’s phone number for new patient appointments is currently down. Until the issue is resolved, you can contact us through our online appointment form. We apologize for the inconvenience. Read more

More About Office of Technology Development Minus iconIcon indicating subtraction, or that the element can be closed. Plus IconIcon indicating addition, or that the element can be opened. Arrow (down) icon.An arrow icon, usually indicating that the containing element can be opened and closed.

SK-MEL-30: Human Melanoma Cell Line

SK1980-526

Description

SK-MEL-30 is one of a series of melanoma cell lines established from patient-derived tumor samples. This cell line expresses wildtype B-Raf and mutant N-Ras (Q61K).

Source

This cell line was established in 1975 from a soft-tissue metastatic site (dermis) in a 66-year-old Caucasian male.

Inventors

  • Lloyd J. Old, MD, former William E. Snee Chair in Cancer Immunology, Memorial Sloan Kettering; former Director, New York Branch, Ludwig Institute for Cancer Research
  • Toshitada Takahashi, MD, formerly at Sloan Kettering Institute, Memorial Sloan Kettering

Key References

  • Carey TE et al. (1976) Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proceedings of the National Academy of Sciences 73: 3278-3282 (Pubmed ID: 1067619)
  • Xing F et al. (2012) Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E) BRAF. Oncogene 31(4): 446-457 (Pubmed ID: 21725359)

Licensing Information

This cell line may be licensed nonexclusively for research or commercial purposes.

Contact Information

  • For licensing requests: Alexandra Buga, MBA, Business Development Analyst, Office of Technology Development, MSK, 646-888-1078, bugaa@mskcc.org
  • For non-licensing requests from academic-research institutions: Frances Weis-Garcia, PhD, Associate Laboratory Member/Head, Antibody& Bioresource Core Facility, MSK, 646-888-2354, weisgarf@mskcc.org

Stage of Development

Ready to use

Indications